PARP1 and ovarian cancer: Indeed, this is the case, as cancer cells with aberrant variants of BRCA1/2 such as breast and ovarian cancers are prone to cell death in the presence of PARP inhibitors, thereby demonstrating synthetic lethality (Fig. 2).